Embargo Policy

Full text of accepted abstracts will be made available to media registrants on April 18, 2023, two weeks before the material goes live to the public. Abstracts will be released to the public on May 2, 2023, at 4:30 p.m. (ET). Researchers and presenters are free to discuss the content of their abstracts throughout this embargo period, but any abstract-related content may not be published until the abstracts are publicly released online.

Updated data, new graphics, and follow-up information to be presented during oral presentation sessions is embargoed until 6 a.m. on the presentation day.

View our 2023 media policies

Publication Exceptions

In exceedingly rare circumstances, ASGCT may grant an exception to the embargo policy in order to comply with regulations from the Securities and Exchange Commission (SEC), other federal law, or international law.

Any exception request must be submitted to ASGCT in writing to CEO David Barrett (dbarrett@asgct.org), Senior Program Manager Alex Peterson (apeterson@asgct.org), Program Manager Kim Durham (kdurham@asgct.org) and Director of Communications Alex Wendland (awendland@asgct.org) at least 48 hours before the conclusion of the public embargo, and must include the following:

Statement that an exception is required to abide by applicable securities laws
Statement that the disclosed information is the absolute minimum necessary to comply with the applicable securities law
The lead author and presenter (both if they are different) copied on any correspondence
Signature of legal counsel

Whenever possible, ASGCT prefers any disclosure follow these guidelines:

Do not include implications or translational interpretations of results
Necessary data presented in qualitative terms rather than quantitative terms
Include the submission to and upcoming presentation at the ASGCT Annual Meeting

For example, a press release stating “we’re hopeful that the research presented at the ASGCT Annual Meeting will bring gene therapy for [insert disease] closer to the clinic, and we’re excited to share additional updates during our presentation,” is a qualitative statement and preferred in the case of an exception. However, a statement such as “in the study submitted to ASGCT, 5 of 7 patients demonstrate no disease symptoms and we’ve applied for FDA fast track designation,” is a quantitative statement and should not be included in a release.